Head-to-Head chemo showdown for rare lymphoma

NCT ID NCT07258680

ENROLLING_BY_INVITATION Disease control Sponsor: N.N. Petrov National Medical Research Center of Oncology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial compares four different chemotherapy combinations to see which works best as a first treatment for peripheral T-cell lymphoma. About 114 newly diagnosed patients will receive one of the regimens, and researchers will measure how many achieve complete remission and track side effects. The goal is to find the most effective and safest option to guide future treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy drugs (doxorubicin, vincristine, etoposide, cyclophosphamide, prednisone, brentuximab vedotin)
What this could lead to: If successful, this trial could identify the most effective and least toxic first-line chemotherapy regimen for peripheral T-cell lymphoma, improving outcomes for newly diagnosed patients.
What could go wrong: This is a single-center study with only 114 participants, so results may not apply to all patients. Chemotherapy side effects can be severe, and the best regimen may still have limited long-term success.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL T-CELL LYMPHOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.